GlassScriptPhysician profile
Alyssa Horton
NPI 1801400353
$1,799.21
in general payments reported to CMS, 2019-2025
32 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $463 · 2023: $404 · 2024: $296 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $294.85 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $152.43 | 2021-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $149.03 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $129.93 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.09 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $119.45 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.60 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $66.01 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $63.02 | 2022-2025 | Farxiga, Breztri |
| Mylan Specialty L.P. | $62.21 | 2023-2024 | Yupelri |
| Abbvie INC. | $61.97 | 2022-2024 | |
| Hologic Sales and Service, LLC | $56.36 | 2023-2025 | Aptima, Acessa Provu System |
| Biohaven Pharmaceuticals, INC. | $41.49 | 2021 | |
| Pfizer INC. | $38.83 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $34.41 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.66 | 2021 | |
| Xeris Pharmaceuticals, INC. | $30.12 | 2022-2023 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $24.91 | 2022 | |
| Sumitomo Pharma America, INC. | $23.96 | 2024 | Gemtesa |
| Tonix Medicines, INC. | $22.95 | 2025 | Tonmya |
| Supernus Pharmaceuticals, INC. | $20.33 | 2022 | |
| Esperion Therapeutics, INC. | $19.08 | 2025 | Nexletol |
| Axonics, INC. | $18.56 | 2022 | |
| Merck Sharp & Dohme LLC | $18.56 | 2022 | |
| Eisai INC. | $18.20 | 2021 | |
| Dexcom, INC. | $16.45 | 2023 | Dexcom G6 Transmitter |
| Avion Pharmaceuticals | $15.40 | 2023 | Methylphenidate Hydrochloride |
| Astellas Pharma US INC | $15.11 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $14.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.17 | 2024 | Xarelto |
| Shield Therapeutics INC | $13.14 | 2023 | Accrufer |
| Sanofi Pasteur INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Horton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.